Rob Davis, Merck CEO (Jacquelyn Martin/AP Images)
May 31, 2024 03:53 PM EDT
Pharma

Mer­ck CEO says Keytru­da is ‘not a re­peat­able mod­el’

Kyle LaHucik

Senior Reporter

CHICA­GO — Can there be an­oth­er Keytru­da?

Mer­ck CEO Rob Davis, whose com­pa­ny makes the $25 bil­lion-a-year can­cer med­i­cine, says it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Har­bour Bio­Med inks deal up to $395M; ORIC re­fines plans for two drugs

Gink­go un­cer­tain over the fu­ture of US gov­ern­ment fund­ing, stock drops

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times